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Abstract
Peroxisome proliferator activated receptor gamma (PPARγ) is a pleiotropic ligand activated
transcription factor that acts in several tissues to regulate adipocyte differentiation, lipid
metabolism, insulin sensitivity and glucose homeostasis. PPARγ also regulates cardiomyo-
cyte homeostasis and by virtue of its obligate role in placental development is required for
embryonic survival. To determine the postnatal functions of PPARγ in vivo we studied glob-
ally deficient neonatal mice produced by epiblast-restricted elimination of PPARγ. PPARγ-
rescued placentas support development of PPARγ-deficient embryos that are viable and
born in near normal numbers. However, PPARγ-deficient neonatal mice show severe lipo-
dystrophy, lipemia, hepatic steatosis with focal hepatitis, relative insulin deficiency and dia-
betes beginning soon after birth and culminating in failure to thrive and neonatal lethality
between 4 and 10 days of age. These abnormalities are not observed with selective
PPARγ2 deficiency or with deficiency restricted to hepatocytes, skeletal muscle, adipo-
cytes, cardiomyocytes, endothelium or pancreatic beta cells. These observations suggest
important but previously unappreciated functions for PPARγ1 in the neonatal period either
alone or in combination with PPARγ2 in lipid metabolism, glucose homeostasis and insulin
sensitivity.
Introduction
Peroxisome proliferator activated receptor gamma (PPARγ) was discovered as an important
ligand-activated transcription factor and pleiotropic regulator of adipocyte differentiation and
lipid metabolism [1]. PPARγ functions in insulin sensitivity and glucose homeostasis [2] also
suggest a prominent role in the metabolic syndrome, or syndrome X, a frequently occurring
constellation of pathophysiologic abnormalities including obesity, insulin resistance, and dysli-
pidemia associated with type 2 diabetes mellitus, hypertension and atherosclerosis [3, 4]. In
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addition to its important functions in adults, PPARγ also plays a crucial role during placental
vascular development. Mice lacking PPARγ die at midgestation with abortive differentiation of
the placental labyrinth and failure to form the primary maternal-fetal vascular exchange inter-
face ([5, 6] and unpublished observations).
Our goal is to determine the postnatal roles of PPARγ by a loss-of-function experimental
strategy. However, pharmacologic inhibitors have not been suitable due to lack of specificity
and potency [7], and placental failure precludes studies of non-conditional loss-of-function.
Therefore, in our initial approach we analyzed embryonic stem cell/blastocyst-derived mice
that were chimeric for homozygous PPARγ deficiency [8]. These experiments confirmed a spe-
cific and obligate role for PPARγ in adipocyte differentiation and adipose tissue development
in vivo [9] and helped define PPARγ’s role in cholesterol metabolism by macrophage [10]. Sub-
sequently, we and others used Cre-loxP to investigate cell-type specific loss of PPARγ function
in adults. These studies revealed that: cardiomyocyte PPARγ participates in cardiac hypertro-
phy [11]; adipocyte PPARγ is required for normal adiposity [12–14] and for insulin sensitivity
in fat and liver, but not in muscle [12]; skeletal myocyte PPARγ is required for normal adipos-
ity and for insulin sensitivity in liver, but not in fat or muscle [15, 16]; hepatic PPARγ is
required to maintain whole body insulin sensitivity, particularly in older animals or in geneti-
cally diabetic backgrounds, and mediates hepatic steatosis [17, 18]; endothelial PPARγ is
important in diet-induced hypertension [19] and lipid metabolism [20]; and mice with
PPARγ-deficient pancreatic beta cells show normal glucose homeostasis and retain antidiabetic
responses to rosiglitazone despite showing islet hyperplasia on a chow diet and blunted islet
expansion on a high fat diet [21]. Isotype-related functions of PPARγ have also been deter-
mined. Global deficiency of PPARγ2, the predominate isoform expressed in adipocytes [22],
with retention of PPARγ1 expression mimics adipocyte-specific deficiency of all PPARγ iso-
forms [23]. Isoform-specific deficiency of PPARγ1 has not been reported.
Taken together, these studies began to elucidate the tissue and lineage-restricted functions
of PPARγ and its isoforms. However, the effects of generalized PPARγ deficiency in the postna-
tal period remained unknown. Determining such effects is important for understanding how
tissue-restricted and isoform-specific functions are integrated, which effects predominate, and
which effects are rate limiting in different physiologic and pathophysiologic settings. Therefore,
to determine the effects of generalized PPARγ deficiency in vivo, we used the MORE-Cre
(Mox2-Cre) allele [24] to conditionally delete PPARγ in epiblast-derived tissues while sparing
placental trophoblast. This approach rescued PPARγ-deficient placental failure and produced
live born mice with severe, generalized PPARγ deficiency. Studies with these animals con-
firmed PPARγ’s role in adipocyte differentiation, revealed new effects in glucose, insulin and
lipid metabolism, extended the appreciation of PPARγ function to circadian rhythms of behav-
ior and metabolism and documented the feasibility of analyzing PPARγ function in adults by
genetic loss-of-function [25–27]. Subsequent experiments substituting Sox2cre for MORECre to
achieve more complete PPARγ deletion in epiblast confirmed rescue of midgestation embry-
onic lethality while administering PPARγ agonists produced fetal growth restriction with
altered trophoblast and microvascular morphogenesis [28]. Angiogenesis-related gene expres-
sion was also altered in the latter stages of pregnancy. We now report that PPARγ-deficient
neonatal mice born fromMORECre-rescued gestations show near complete absence of adipose
tissue at birth, severe alterations in lipid and glucose metabolism with functional insulin defi-
ciency and diabetes and failure to thrive usually resulting in death by the second week of life.
These findings suggest important but previously unappreciated consequences of PPARγ1 defi-
ciency in the neonatal period either alone or in combination with PPARγ2 in lipid metabolism,
glucose homeostasis and insulin sensitivity.
PPARγ Deficiency Causes Neonatal Lipodystrophy and Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0160636 August 9, 2016 2 / 14
Department of Pathology, Brigham and Women’s
Hospital (DSM). The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Abbreviations: P0, P1, etc., postnatal day 0,
postnatal day 1, etc; NEFA, non-esterified fatty acid;
FPLC, fast protein liquid chromatography; WAT, white
adipose tissue; BAT, brown adipose tissue.
Results
Epiblast-restricted PPARγ deficiency rescues placental failure and
reveals neonatal lethality
Breeding PPARγ+/- x PPARγ+/- mice did not yield any PPARγ-/- neonates among more than
500 live births (Table 1A) [5, 6]). In contrast, breeding PPARγF/F females to PPARγ+/-:MORE+/Cre
males yielded substantial numbers of live PPARγ-/F:MORE+/Cre newborns (Table 1B). 95% of the
floxed PPARγ allele in adults that survive from these matings was recombined to the null allele
[25]. More extensive recombination is expected in mice that die during the neonatal period such
that these adult results likely underestimate the amount of recombination in the neonates studied
here that succumb. In addition, PPARγmRNAwas present but at very low levels in the small
amounts of periuterine adipose tissue found in adult female mutant mice [25] suggesting that any
such cells in these mosaic adults or neonates likely represent escape from recombination.” There-
fore, conditional epiblast-restricted recombination directed by theMORECre allele efficiently res-
cued embryonic lethality as previously reported [25] and similar to the results reported using
Sox2cre [28]. However, both parental genotype matings produce fewer than expected neonates
bearing placental tissues with heterozygous deficiency for PPARγ (PPARγ-+- in Table 1A or
PPARγ-/F in Table 1B) [29, 30].
PPARγ-/F:MORE+/Cre neonates were identifiable by gross inspection at birth displaying der-
mal hypopigmentation and a prominent interscapular concavity (Fig 1A). The latter reflected
absence, or near absence of brown adipose tissue (BAT) (Fig 1B–1D). Occasionally, a small
amount of residual tissue (as little as 5 mg could be appreciated visually) was present (Fig 1D). In
Table 1. Epiblast-restricted recombination rescues PPARγ-deficient embryonic lethality.
A
PPARγ+/- x PPARγ+/-
PPARγ O E1 E2
+/+ 194
38%
127
25%
168
33%
+/- 314
62%
254
50%
340
67%
-/- 0
0%
127
25%
-
B
PPARγF/F x PPARγ+/-:MORE+/Cre
MORE
+/+ +/Cre
PPARγ O E O E
+/F 127
27%
117
25%
141
30%
117
25%
-/F 96
21%
117
25%
104
22%
117
25%
For each genotype the tables show the number and percent of live born neonates observed (O) and expected assuming Mendelian inheritance (E). (A)
PPARγ+/- female x PPARγ+/-male. (B) PPARγF/F female x PPARγ+/-:MORE+/Cre male. E1, expected assuming survival of all gestations until genotype
determination. E2, expected assuming PPARγ-/- embryonic lethality. Global PPARγ deﬁciency is uniformly fatal prior to birth. In contrast, substantial
numbers of PPARγ-/F:MORE+/Cre neonates are born with epiblast-restricted PPARγ deﬁciency. However, fewer neonates than expected are observed from
PPARγ haploinsufﬁcient placentas in the absence of MORECre (PPARγ+/- and PPARγ-/F in A and B, respectively). A. p < 0.0001 vs. E1; p = 0.014 vs. E2. B.
p = 0.012, 0.021 and 0.044 observed vs. expected for all genotypes, for mice inheriting Cre and for mice not inheriting Cre, respectively [29, 30].
doi:10.1371/journal.pone.0160636.t001
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addition, PPARγ-/F:MORE+/Cre newborns were 9% smaller than control littermates at birth
(p = 0.002, Fig 1E) and, despite successful nursing as judged by the presence of gastric milk, failed
to gain weight postpartum: PPARγ-/F:MORE+/Cre newborns were not significantly larger at P3
than at P1 (p> 0.06, Fig 1E). In contrast, control littermates gained weight daily between P0 and
P3 (p< 0.0003 at each day, Fig 1E) and were 31% larger than PPARγ-/F:MORE+/Cre neonates at
P3 (p = 0.00001, Fig 1E). Significantly, the difference in birth weight was comparable to the
weight of BAT in normal P0 neonates (~100 mg, data not shown) suggesting that other organs
attained normal size during embryogenesis in the absence of PPARγ. The majority of these exten-
sively PPARγ deficient neonates either failed to thrive (see Methods for criteria) and were eutha-
nized at P5 or P8 or were less severely affected but found dead at P12 or P13 (Fig 1G, p< 0.0001,
log-rank (Mantel-Cox) test compared to non-mutant animals). However, a small number (Fig
1G) survive to weaning thus enabling experiments in adults as previously reported [25, 27].
Fig 1. Failure to thrive and neonatal lethality in PPARγ-/F:MORE+/Cre mice. (A) PPARγ-/F:MORE+/Cre mice (right) show dermal hypopigmentation and an
interscapular concavity (thick arrow, right panel) corresponding to the position of the interscapular brown fat pad in normal mice (thick arrow, left panel). Thin
arrows designate retinal pigment indicating the paleness of this PPARγ-/F:MORE+/Cre neonate is not due to albinism. (B-D) Interscapular adipose tissue was
virtually absent in PPARγ-/F:MORE+/Cre P3 neonates. The interscapular region contains BAT in control (dashed outline, B), but not in mutant (dashed
outline, C) P3 neonates. Occasional mutants retained small amounts of interscapular tissue consisting primarily of white adipose tissue (WAT)-like tissue
(dashed outline, D). (E) Body weight of neonatal mice from PPARγF/F x PPARγ+/-:MORE+/Cre matings. PPARγ-/F:MORE+/Cre mice are slightly smaller than
littermates at birth (* p < 0.002), subsequently fail to gain weight in spite of apparently normal suckling and the appearance of a milk spot and are markedly
smaller than littermates at P3 (*** p = 0.00001). In contrast, littermates gain weight daily (** p < 0.0003 vs. previous day). (F) Organ weights showing
selective hepatomegaly in P3 PPARγ-/F:MORE+/Cre mice (* p < 0.05; NS, p > 0.05). (G) Neonatal lethality of PPARγ-/F:MORE+/Cre mice. The majority of
PPARγ-/F:MORE+/Cre mice were euthanized at humane endpoints or found dead between P5 and P13 (* p < 0.0001). In E and F “Control” indicates
combined results for PPARγ+/F:MORE+/+, PPARγ-/F:MORE+/+ and PPARγ+/F:MORE+/Cre neonates.
doi:10.1371/journal.pone.0160636.g001
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Hepatomegaly, hepatitis and hepatocellular necrosis in PPARγ deficient
neonates
Livers of mutant mice were normal size and appearance at birth (not shown). However, P3
mutant mice showed marked hepatomegaly (Fig 1F) with macroscopic pallor (Fig 2A and 2B),
microvessicular steatosis, and hepatocellular necrosis with associated acute hepatitis and hem-
orrhage (Fig 2C–2F and not shown). Extramedullary hematopoiesis, normal at this age (Fig 2C
and 2E arrows) was greatly diminished or absent in mutant mice (Fig 2D and 2F). Instead,
focal collections of neutrophils were frequent in mutant liver (Fig 2F arrows) immediately adja-
cent to steatotic hepatocytes reflecting active hepatitis. Pancreata of mutant mice were normal
size at P3 (Fig 1F).
Fig 2. Hepatic steatosis and normal bowel in PPARγ-/F:MORE+/Cre neonatal mice. (A and B) The abdominal
contents reveal pale, enlarged liver (arrows) in P3 PPARγ-/F:MORE+/Cre mice (B) compared to normal controls (A).
(C-F). H & E histology of the liver reveals microvessicular steatosis and focal hepatitis in mutant mice (D and F) but
absence of steatosis or inflammation and presence of normal extramedullary hematopoiesis in control mice (C and
E). Short and long arrows in E and F distinguish normal extramedullary hematopoiesis (E) from acute inflammation
(F with neutrophils) in control (E) and PPARγ-/F:MORE+/Cre (F) mice, respectively. (G) Gastrointestinal tracts were
dissected from duodenum to rectum, loosely coiled on a flat surface with duodenum central and rectum peripheral,
and photographed. PPARγ-deficient small and large bowel is normal without evidence of ischemia, hemorrhage,
inflammation or necrosis.
doi:10.1371/journal.pone.0160636.g002
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Small and large bowel were grossly normal in mutant neonates (Fig 2G) without gross or
histologic evidence of ischemia, hemorrhage or necrosis (Fig 2G and not shown). The differ-
ences in gross appearance of bowel are consistent with normal variation and variable bowel
contents.
Severe lipodystrophy with lipemia and hyperlipoproteinemia in PPARγ
deficient neonates
While the interscapular BAT fat pad was entirely absent in most mutant neonates (Fig 1A–1D)
necropsy revealed normal size heart, lung, spleen and kidney at P3 (Fig 1F), In contrast, axil-
lary, inguinal and gonadal WAT was well formed in control P3 neonatal mice (Fig 3A, 3B, 3D,
3F and 3H) but was largely absent in PPAR+/-:MORE+/Cre animals (Fig 3A, 3C, 3E, 3G and 3I).
In place of WAT were small amounts of fragile, wispy tissue with blood vessels rendered espe-
cially prominent in relief (Fig 3C) and lacking histologic evidence of maturing adipocytes (Fig
3G).
Prominent dermal hypopigmentation was also observed in mutant P3 neonates (Figs 1A,
3A, 3D and 3E). In addition, nascent subcutaneous adipose tissue, appreciated grossly in con-
trol skin as translucent, refractile collections (Fig 3D) and histologically as fibrovascular tissue
with collections of recognizable adipocytes (Fig 3F inset), was also absent or severely reduced
Fig 3. Lipodystrophy in PPARγ-/F:MORE+/Cre neonatal mice. Axillary, inguinal and subcutaneousWAT is
significantly diminished and lacks mature adipocytes in PPARγ-/F:MORE+/Cre mice. (A-E) Skin was removed
intact from euthanized P3 mice, restrained in a flattened position, fixed in 10% NBF and photographed from
the deep aspect. PPARγ-/F:MORE+/Cre mice show greatly diminished axillary, thoracic and inguinal WAT
(arrows in A) that contained wispy fibrovascular connective tissue, decreased mature adipocytes, and
normal-appearing blood vessels (A, C, E, G, I) in place of well-formedWAT in controls (A, B, D PPARγ-/F:
MORE+/+; F, H PPARγ+/F:MORE+/Cre;). Control (D) but not mutant (E) skin also showed refractile collections
of subcutaneous adipose tissue that were diffusely distributed both superficial and deep (arrows in F and H)
to the panniculus carnosus and were largely lacking in mutant skin (G and I). Dashed lines in A indicate the
planes of microtome sectioning used for the histologic images presented in F-I. Long and short arrows in C
indicate grossly lipemic and non-lipemic blood, respectively. Dashed rectangles in F and G indicate the areas
shown at higher power in the insets. Scale bars: B, C 3 mm; D, E 1 mm.
doi:10.1371/journal.pone.0160636.g003
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in PPARγ-/F:MORE+/Cre neonates (Fig 3E and 3G inset). Instead, mutant subcutis often con-
tained small amounts of skeletal muscle (panniculus carnosus) directly opposed to dermis
without the intervening and/or surrounding adipocyte collections present in controls. By P3
well-formed subcutaneous adipose tissue was present in controls (Fig 3H) but largely absent in
mutants (Fig 3I).
Mutant neonatal mice were also markedly lipemic. This was immediately apparent as pink/
white blood readily observed in vivo and ex vivo (Fig 3C long arrow, Fig 4A) and was due in
part to a 4-5-fold elevation of free fatty acids in serum (Fig 4B and not shown). FPLC and
quantitative assay for serum lipoprotein and lipids revealed that total serum cholesterol was
also elevated approximately 50% in mutant neonatal mice including elevation of cholesterol
content in chylomicrons, VLDL and LDL but not in HDL (Fig 4C). More strikingly, total
serum triglyceride was elevated almost ten-fold, with significant elevation in triglyceride con-
tent of chylomicrons, VLDL, LDL and HDL and elevation of total serum glycerol (Fig 4D). In
Fig 4. Lipemia with elevated serum lipids and lipoproteins in severely PPARγ deficient PPARγ-/F:MORE+/Cre neonatal mice. (A) Grossly lipemic
serum. Abdominal skin was reflected and viewed from the deep aspect. Blood in control mice is dark red (left, arrows). Blood in mutant mice is light pink
(right, arrows) reflecting lipemia. Gross lipemia was also evident in serum viewed in capillary tubes as prepared frommutant (right) compared to control (left)
mice. (B) Serum non-esterified fatty acid levels reveal lipemia in P0, P1 and P3 mutant neonates. (C-E) Serum was analyzed by FPLC followed by
quantitative assay for cholesterol, triglyceride, glycerol and lipoprotein particle size. (C.)Total serum cholesterol was elevated approximately 50% in mutant
neonatal mice including elevation of cholesterol content in chylomicrons, VLDL and LDL but not in HDL. (D) Total serum triglyceride was elevated almost
ten-fold in mutant neonatal mice with significant elevation in triglyceride content of chylomicrons, VLDL, LDL and HDL and elevation of total serum glycerol.
(E) VLDL particles carrying cholesterol and triglyceride and HDL carrying triglyceride were 8%, 4% and 6% larger in diameter, respectively, in mutant
neonatal mice while other values varied by less than 2%. * p < 0.05; NS, p > 0.05. “Control” indicates combined values for PPARγ+/F:MORE+/+, PPARγ+/+:
MORE+/Cre and PPARγ+/F:MORE+/Cre neonates. The numbers of mice analyzed of each genotype is indicated in parentheses. Black asterisks, statistically
significant difference between PPARγ-deficient neonates and pooled control groups. Grey asterisks, statistically significant difference between the control
groups indicated. See also S1 Table.
doi:10.1371/journal.pone.0160636.g004
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addition, lipoprotein particle size was altered in mutants (Fig 4E): VLDL particles carrying cho-
lesterol and triglyceride and HDL carrying triglyceride were 8%, 4% and 6% larger in diameter,
respectively, while other values, some showing statistically significant differences, varied by less
than 2%. Despite some statically significant differences (Fig 4C–4E, grey asterisks) the three
different control genotypes used in these experiments each show the same phenotype relative
to the PPARγ-deficient group and are more similar to each other than they are to PPARγ-defi-
cient neonates (Fig 4C and 4E and S1 Table).
Severe diabetes mellitus with ketosis and relative insulin deficiency in
PPARγ deficient neonates
PPARγ-deficient neonates were severely diabetic beginning at P1 (serum glucose at P3 355 +/-
155 mg/dL in MORE+/Cre:PPARγ-/F, n = 7 vs. 91 +/- 11 mg/dL in MORE+/Cre:PPARγ+/F, n = 6,
Fig 5. Diabetes mellitus and relative insulin deficiency in severely PPARγ deficient PPARγ-/F:MORE+/Cre neonatal mice. (A) Serum glucose levels
reveal severe diabetes mellitus in P1 and P3, but not P0, mutant neonates. (B) Serum BHA levels reveal ketonemia in P1 and P3, but not P0, mutant
neonates. (C) Normal serum insulin in diabetic P3 mutant mice. (D) IHC for insulin in pancreatic islet beta cells of wild type and severely PPARγ-deficient
PPARγ-/F:MORE+/Cre neonatal mice. Comparable staining is observed in pancreas from P0 (upper panels) mutant (right) and control (left) mice. At P3 (lower
panels), pancreas frommutant mice (right) shows less intense and more diffuse staining for insulin than pancreas from control mice (left). Mutant pancreas
reproducibly showed greener counter staining than wild type likely reflecting systemic effects on pancreatic cells in mutant neonates even at P0. In A-C: *
p < 0.05; NS, p > 0.05.
doi:10.1371/journal.pone.0160636.g005
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p = 0.0008) with ketonemia (Fig 5A and 5B, respectively). Although insulin resistance was antici-
pated in these PPARγ-deficient, severely lipodystrophic animals, circulating insulin levels were
“inappropriately” normal (7.6 +/- 10.1 ng/ml inMORE+/Cre:PPARγ-/F, n = 7, vs. 7.4 +/- 7.4 ng/ml
inMORE+/Cre:PPARγ+/F, n = 6. P = 0.98) (Fig 5C). In addition, while pancreatic islets were
approximately normal in size and distribution (Fig 5D) IHC revealed decreased intensity insulin
staining in presumptive pancreatic islet beta cells of PPARγ-/F:MORE+/Cre compared to control
neonates at P3 (Fig 5D bottom) while insulin staining was more comparable at P0 (Fig 5D top).
Discussion
Despite numerous studies of tissue-restricted and isoform-specific functions of PPARγ determin-
ing the integrated functional consequences of this pleiotropic regulator of adipogenesis, insulin
sensitivity and glucose homeostasis in vivo has remained problematic because PPARγ-deficient
placental failure uniformly causes embryonic lethality [8–12, 15–23]. To address this important
issue we generated mice with global PPARγ deficiency using a targeted Cre “knock-in”/null allele
of Mox2 (MOREcre) that unexpectedly is expressed in derivatives of epiblast but not trophecto-
derm or primitive endoderm. Such expression, that does not mirror expression of endogenous
Mox2 is probably related to sequences retained in the mutant allele including a phosphoglycerate
kinase “promoter” used to drive neor expression in embryonic stem cells [24]. The MORECre
allele provided a convenient experimental tool to differentiate extraembryonic from embryonic
gene expression and produce live born mice with mutations, such as PPARγ-/-, that are normally
embryo-lethal due to placental failure. AlthoughMORECre/Cre mice die young, MORE+/Cre mice
(obtained from Dr. Philippe Soriano) used in the experiments reported here exhibited only mild
muscular weakness, as reported [24], but normal breeding performance in our colony.
Our observation of survival to birth of PPARγ-/F:MORE+/Cre embryos is consistent with
intrinsic placental failure [5, 6], rather than effects in embryos per se, as the cause of embryonic
lethality in globally deficient PPARγ gestations: functionally heterozygous PPARγ-/F tropho-
blast in the context of epiblast-restricted expression of MORECre rescues null-lethal placental
failure. In addition, the compromised survival observed by gestations with heterozygous
PPARγ deficiency (Table 1A and 1B) is consistent with the structural abnormalities reported in
PPARγ+/- placentas that are similar to, but less severe than, those leading to uniform lethality
in PPARγ-/- placentas [5, 6]. Future studies to identify embryos undergoing intrauterine
demise with PPARγ+/- placentas will validate this prediction and help determine why haploin-
sufficient embryos are underrepresented.
To our knowledge PPARγ-/F:MORE+/Cre mice provide the most severe model of global post-
natal PPARγ deficiency studied to date: the vast majority of cells in the tissues examined from
mosaic PPARγ-/F:MORE+/Cre mice are genotypically PPARγ-/- [25] resulting in severe and
global functional PPARγ deficiency. The few PPARγ-/F:MORE+/Cre mice that survive to wean-
ing allow studies of severe PPARγ deficiency in adults as previously reported [25–27]. Sox2Cre,
which potentially provides more efficient recombination in epiblast [31], has been used to
study PPARγ in placenta [28] and may produce more complete PPARγ deficiency in embryos.
However, the low viability of PPARγ-/F:MORE+/Cre neonates (Fig 1G) suggests that more effi-
cient recombination by Sox2Cre may also decrease the hypothesized mosaic rescue and result in
uniform neonatal lethality thus precluding studies in adults. In this case future comparisons of
MORECre and Sox2Cre may elucidate the tissues and cell types in which PPARγ is required for
survival beyond the neonatal period.
PPARγ-/F:MORE+/Cre neonates were immediately recognizable by gross inspection at birth
by virtue of their dermal hypopigmentation and absence of an interscapular brown fat pad.
They also displayed diminished subcutaneous adipose tissue examined both grossly and
PPARγ Deficiency Causes Neonatal Lipodystrophy and Diabetes
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histologically. These observations are consistent with the conclusion from numerous previous
studies that PPARγ is required to form mature adipose tissue in adults. Small amounts of resid-
ual interscapular tissue and small numbers of differentiated adipocytes that were observed in a
few PPARγ-/F:MORE+/Cre neonates probably resulted from escape from recombination of a
small number of PPARγ-/F, functionally heterozygous cells that still express PPARγ allowing
them to enter and expand within the adipocyte lineages in these mosaic animals. Other cells
present at sites normally undergoing adipogenesis may include stromal cells and adipocyte pre-
cursors whose differentiation from mesenchymal progenitors does not require PPARγ [9, 22,
32, 33]. Organogenesis was otherwise largely normal in PPARγ-/F:MORE+/Cre mice that were
only 9% smaller than control littermates at birth, primarily reflecting absence of the interscapu-
lar BAT fat pad. However, such mice failed to gain weight despite nursing successfully and
eventually died between P5 and P13 with virtual absence of brown and white adipose tissue,
severe hepatic steatosis, lipemia, functional insulin deficiency and diabetes with ketosis. The
fact that most of these effects were not observed in mice with either global deficiency of
PPARγ2 or deficiency of both PPARγ1 and PPARγ2 specifically in adipocytes or several other
cell types [11–23] suggests that they reflect previously unappreciated functions of PPARγ1 in
one or more tissues either alone or in combination with PPARγ2.
Gastrointestinal bleeding was observed in the viable PPARγ-/- neonate produced by wild type
tetraploid rescue [6]. In contrast, none of five PPARγ-/F:MORE+/Cre neonates examined in the cur-
rent report showed ischemia, hemorrhage or necrosis of small or large bowel suggesting that the
original observation was not related solely to PPARγ deficiency. However, we cannot exclude the
possibility that small numbers of PPARγ-expressing cells present in PPARγ-/F:MORE+/Cre mosaic
mice are sufficient to rescue a PPARγ-deficient ischemic bowel phenotype. More subtle effects in
small and large bowel that might result from PPARγ deficiency remain to be evaluated.
PPARγ-/F:MORE+/Cre neonates were diabetic with normal plasma insulin suggesting that
although insulin was expressed by pancreatic β-cells quantitative insulin production, glucose
sensing and/or insulin secretion was impaired in the absence of PPARγ. Onset of severe lipemia
soon after birth likely reflects the paucity of adipocytes and the resultant inability to store the
large amounts of triglyceride and cholesterol newly encountered during the transition from
low fat intrauterine nutrition to the high fat diet of nursing. Elevated serum lipids are associ-
ated with exacerbation of acute pancreatitis (“lipotoxicity”) and lipoapoptosis is a prominent
feature of diabetes [34, 35] suggesting that lipemia may contribute to diabetes in PPARγ-/F:
MORE+/Cre neonates. Defects in insulin secretion have also been reported secondary to absence
of BAT [36] suggesting that diminished BAT in PPARγ-/F:MORE+/Cre neonates may also
impair glucose metabolism via effects on insulin release. However, even if insulin is quantita-
tively decreased in PPARγ-/F:MORE+/Cre pancreas this is unlikely to fully explain the inappro-
priately normal levels of circulating insulin observed in the presence of extreme hyperglycemia
(Fig 5A and 5C). In contrast to neonates, PPARγ-/F:MORE+/Cre mice that survive to adulthood
show normal serum glucose with greatly elevated plasma insulin [25, 26] suggesting insulin
resistance and consistent with predictions from cell culture and pharmacologic studies. The
reasons for these differences between neonatal and adult PPARγ-/F:MORE+/Cre mice are
unclear but may be related to factors that allowed the latter mosaic animals to escape neonatal
lethality. In addition, mice with PPARγ-deficient pancreatic β-cells show normal glucose
homeostasis despite abnormalities in islet mass [21]. It thus seems likely that insulin resistance
and defective insulin delivery to the circulation may combine to produce especially severe glu-
cose intolerance in PPARγ-/F:MORE+/Cre neonates and that this combination of defects does
not persist in those animals that survive to adulthood. For example, changes in PI3K, FOXO or
in insulin and IGF1 receptors can have competing effects on glucose and insulin metabolism
that could help explain why surviving PPARγ-deficient adults are euglycemic with elevated
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plasma insulin [25]. However, investigating these and other molecular hypotheses will first
require determining which tissues are responsible for these PPARγ-deficient phenotypes. As a
practical matter administering exogenous insulin to PPARγ-/F:MORE+/Cre neonates may tran-
siently improve glucose tolerance and prevent neonatal lethality thus extending survival of a
greater fraction of PPARγ-deficient animals for experimental analysis as adults.
Conclusions
PPARγ-deficient neonatal mice were rescued from embryonic lethality by epiblast-restricted
recombination and showed marked lipodystrophy with diabetes but inappropriately “normal”
levels of serum insulin. This constellation of features suggests that PPARγ1 plays previously
unappreciated functions during the neonatal period either alone or in combination with
PPARγ2 in lipid metabolism, glucose homeostasis and insulin sensitivity.
Materials and Methods
Mice
All animal procedures were performed in accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health and were
approved by the Center for Animal Resources and Comparative Medicine at Harvard Medical
School. All efforts were made to minimize suffering. Mice bearing the MOREcre allele in a 129/
SvSor genetic background [24] and mice bearing a floxed allele of PPARγ in a mixed 129/Sv:
C57BL/6:FVB genetic background [37], obtained from Drs. Philipe Soriano and Dr. Frank
Gonzalez, respectively, were maintained in a SPF barrier colony on standard lab chow and
water ad libitum. Copulation plugs from virgin female mice mated with male mice were
detected between 7 AM and 12 pm and defined day 0.5 (P0.5) of gestation. Newborn mice were
genotyped on the day of birth. Health status was monitored daily thereafter until P22 and
weights were recorded daily on P0-P3 in 20 neonatal animals. Animal suffering and distress
were minimized by euthanasia when humane endpoints were met. Animals were euthanized
by decapitation when they failed to grow, showed decreased skin turgor reflecting dehydration
and were debilitated with decreased mobility that impaired suckling. This occurred at P5 and
P8 in 11 and 3 animals, respectively. Two and one PPARγF/-:MOREcre/+ mutant animals
were found dead at P12 and P13, respectively without meeting the criteria for euthanasia on
the previous day. Three mutant animals that did not meet the criteria for euthanasia survived
throughout the observation period and became eligible for experiments as adults. None of the
non-mutant animals met the criteria for euthanasia or died during the observation period.
Genotypes reported are those at the time of fertilization as deduced from analysis of neonatal
tissue biopsies by allele-specific PCR as described previously [38]. Subsequent MORE-Cre-
mediated recombination during embryogenesis produced extensive mosaicism at the time of
genotype determination in mice bearing both a MORECre and PPARγF allele. Necropsies were
performed essentially as described [39].
Histology and Immunohistochemistry
Tissues were fixed (10% neutral buffered formalin) for 24 hours by immersion after dissection
with or without preliminary vascular infusion with 10% neutral buffered formalin beginning in
the left ventricle. Eight-μm paraffin sections were stained with hematoxylin and eosin or were
immunostained for insulin using DAB as chromogen and Methyl Green as counterstain as
described [40]. Images was obtained either using Nikon digital camera or Aperio ScanScope
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XT at 40 x lens setting by the Tissue Microarray and Imaging Core Facility of the Dana-Farber/
Harvard Cancer Center.
Serum Chemistry
Neonatal mice were euthanized by decapitation using a fresh blade. A capillary micropipette
was used to transfer blood from the decapitation site to a 1.5 ml microcentrifuge tube. After 15
minutes tubes were centrifuged at room temperature and the serum layer was transferred to a
fresh tube and stored at –8°C until analyzed. Glucose, β-hydroxybutyrate and NEFA were
determined by enzymatic assay with chromogenic substrates (Sigma Chemical GAGO20-1KT,
MAK041-1KT and MAK044-1KT, respectively). Insulin was determined by radioimmunoas-
say (Linco Research/EMDMillipore Sensitive Rat Insulin RIA). FPLC, determination of serum
lipoproteins, and assay of triglyceride, glycerol and cholesterol was done by LipoSEARCH
Analysis at Skylight Biotech, Inc., Tokyo, Japan.
Statistical analysis
Values presented are mean +/- standard deviation. Weights and serum chemistry were com-
pared using Student’s t-test. Inheritance was compared by Chi-square test and Binomial test
for all genotypes and for pairs of genotypes, respectively. Survival was compared by log-rank
Mantel-Cox test. P-value of 0.05 was taken to indicate statistically significant differences
between the populations sampled. Statistical analyses were performed using GraphPad Prism
version 6 software for Macintosh (GraphPad Software, San Diego, CA, USA).
Supporting Information
S1 Table. (related to Fig 4C–4E) Serum lipoprotein and lipids values obtained by FPLC and
quantitative assay for individual and pooled control groups and for PPARγ-deficient neo-
nates. The number of mice analyzed of each genotype is indicated in parentheses. These data
are presented in graphical form in Fig 4C–4E. Grey backgrounds and white text indicate statis-
tically significant differences between the groups indicated in the table. Some of these neonates
are from matings of PPARγ+/F:MORE+/Cre females and PPARγ-/F males. In such neonates
inheriting maternal MORECre it is not possible to determine if their paternal PPARγ allele is
PPARγ- or PPARγF because near-complete recombination renders the latter undetectable as
PPARγF. Data from these mice is combined with neonates with unambiguous inheritance of
a PPARγF allele. If the allele in question is designated “N” the problematic genotypes are
PPARγ+/N:MORE+/Cre and PPARγF/N:MORE+/Cre and their data is combined with unambigu-
ous PPARγ+/F:MORE+/Cre and PPARγF/F:MORE+/Cre neonates, respectively.
(PDF)
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